Novel therapies for HIV patients who have failed anti-retroviral therapies & 12th Anniversary of the B2DG-Ramani Aiyer-04/14/2015 - 6:00pm

Event Information
Event Topic: 
Novel therapies for HIV patients who have failed anti-retroviral therapies & 12th Anniversary of the B2DG
Event Date: 
04/14/2015 - 6:00pm
Event Location: 
Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto CA
Speaker Information
Event Speaker: 
Ramani Aiyer
Event Speaker Title: 
Principal
Event Speaker Company: 
Shasta Bioventures
Event Speaker Bio: 

Ramani A. Aiyer heads Shasta BioVentures, a Life Sciences R&D and Business Development consultancy offering strategic advisory and project management services. Currently, he serves part-time as Chief Scientific Officer of STAR Biotech, a start-up focused on discovery and development of novel therapies for Ewing’s Sarcoma. Ramani has a PhD in Biochemistry from Harvard, did post-doctoral research at Stanford and Dana-Farber Cancer Institute, and MBA from University of California, Berkeley. He has over 20 years’ experience in the bio-pharmaceutical industry, with major roles in R&D strategic planning, mentoring scientists and leading project teams. Earlier, Ramani was Chief Scientific Officer at Actis Biologics (INDIA), a start-up bio-therapeutics company, and prior to that Senior Vice President, R&D Strategic Planning at Piramal Life Sciences (INDIA). Ramani’sother roles have included management consulting, and senior positions at Genentech, TransMed Biotech, LifeScan (acquired by Johnson & Johnson), and Sugen (acquired by Pharmacia/Pfizer.

Event Details
Cost: 
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins
Event Details: 

Anti-retroviral therapies (ART) have revolutionized treatment options for HIV patients giving them a new lease of life from what used to be essentially a death warrant when found to be infected with HIV. Of the 2 million HIV-infected patients in US and EU, about 100,000 (5%) fail ART for a variety of reasons and will eventually succumb to the disease. This is a vast unmet need and the talk will focus on current approaches to meet this challenge. In particular, the talk will describe the efforts at TheraBiol Inc.(http://www.therabiol.com), a Bay area start-up founded in May 2012 by a core group of scientists, physicians and entrepreneurs with the support of the QB3 Incubator Program (www.qb3.org) at UCSF. The company is headed by Dr. Girish N. Vyas, Founder & CEO, who is Emeritus Professor at UCSF and a world authority on Virology and Transfusion Medicine.